2026-01-19
ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension
Shanghai, China, January 19, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that its subsidiary, ImmuneCare Biopharmaceuticals (Shanghai) Co.,
View more
2026-01-14
Palverafusp α (IMM2510) Receives NMPA Approval for Phase II/III Clinical Trial in Endometrial Cancer
Shanghai, China, January 14, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the Investigational New Drug (IND) application for a Phase II
View more
2026-01-12
ImmuneOnco Biopharmaceuticals' timdarpacept (IMM01) Receives NMPA Approval for Clinical Trial in Atherosclerosis
Shanghai, China, January 12, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that the clinical trial application for its self-developed timdarp
View more
2026-01-09
ImmuneOnco to Attend 44th Annual J.P. Morgan Healthcare Conference and Present Corporate Overview at Biotech Showcase™
Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44t
View more
